Oncotelic Therapeutics Inc - OTLC STOCK NEWS

Oncotelic Therapeutics (OTCQB:OTLC) has announced that CEO Vuong Trieu will deliver a featured presentation at the SWCR 2025 Conference on March 24th, focusing on Transforming Growth Factor Beta 2 (TGFB2) research. The presentation will explore TGFB2's role in cancer, lupus, and aging pathways.

The research highlights how high TGFB2 expression affects tumor-associated macrophage infiltration, disrupts antigen presentation, and creates resistance to immunotherapy. A significant portion will cover the development of OT-101, their antisense therapeutic targeting TGFB2, currently in Phase 3 clinical trials (STOP-PC study) for pancreatic ductal adenocarcinoma.

The presentation will examine how TGFB2 inhibition, either alone or combined with immune checkpoint inhibitors or interferon-based strategies, could enhance immune response and therapeutic efficacy. Dr. Trieu emphasizes TGFB2's role as a master regulator of immune suppression across multiple chronic diseases.

Oncotelic Therapeutics (OTCQB:OTLC) has announced the implementation of its AI platform PDAOAI, designed for document search and analysis in knowledge-based industries. The platform, accessible via PDAO tokens, uses advanced semantic filtering and LLM-based contextual answering to enable precise queries across large document sets.

The system has already demonstrated success at Sapu Bioscience, a subsidiary of GMP Biotechnology (where Oncotelic holds 45% ownership), helping achieve GMP compliance within one year through efficient staff training and SOP implementation. The platform will be governed through Pet2DAO using PDAO tokens, ensuring transparent, community-driven governance.

Oncotelic Therapeutics (OTCQB:OTLC) announced its upcoming presentations at SITC 2024, led by Dr. Cynthia Lee, VP of R&D. The company will present three abstracts focusing on TGFB2 therapeutics and cancer research:

1. Abstract 198: Examining TGFB2 mRNA levels' interaction with various markers in PDAC survival
2. Abstract 218: Studying prognostic impact of TGFB2 mRNA levels in low-grade gliomas
3. Abstract 1444: Meta-analysis comparing treatments for unresectable PDAC tumors

Dr. Lee, who leads the company's R&D programs and GMP facility in San Diego, will present the Sapu Bio pipeline of TGFB2 therapeutics.

Oncotelic Therapeutics (OTCQB:OTLC) has announced its fourth publication in its TGFB2 research series. Clinical data revealed significant survival improvements in pancreatic cancer patients with low expression levels of both TGFB2 and either IRF9 or IFI27, extending median overall survival from 16-20 months to 72 months. This validates the therapeutic potential of targeting IRF9 and IFI27 knockdown in TGFB2 therapeutics. The company has published four peer-reviewed articles focusing on TGFB2's role in various cancers, including pancreatic ductal adenocarcinoma, low-grade gliomas, and pediatric diffuse intrinsic pontine glioma.

Oncotelic Therapeutics (OTCQB:OTLC) announced its participation at the Precision in Drug Discovery & Preclinical Summit in San Diego. Dr. Wen-Han Chang, Nanomedicine Sr. Manager, and Dr. Tara Zand, Research Scientist, presented the company's Sapu Bio pipeline of TGFB2 therapeutics. Both scientists are focused on developing treatments for pancreatic and brain cancers through nanomedicine and precision drug development approaches.

Oncotelic Therapeutics (OTCQB:OTLC) announced that Product Manager Scott Myers will present at the 2nd Global Summit on Artificial Intelligence. The digital summit focuses on 'Pioneering the New Era: Advancing Global Development through Artificial Intelligence.' Myers will discuss the PubMed Corpus Builder, part of the Orion AI Suite developed by Sapu Bioscience

The PubMed Corpus Builder uses AI and LLMs to create comprehensive document corpora from the PubMed Central Database. It generates multiple search queries, downloads documents, and refines selection using vector search. The tool can identify documents with specific types of graphs and interpret them using multimodal technology. This system significantly accelerates the research process, allowing scientists to efficiently filter through hundreds of documents in minutes.

Oncotelic Therapeutics (OTCQB:OTLC) announced that its CEO, Dr. Vuong Trieu, will present at the 20th Annual Congress of International Drug Discovery Science & Technology in Budapest, Hungary, from June 17-19, 2024. Dr. Trieu will discuss OT-101, an antisense therapeutic targeting TGFB2, currently in phase 3 clinical trials for pancreatic cancer and glioblastoma. The presentation will also cover the potential of OT-101 in treating colorectal cancer (CRC), supported by clinical and bioinformatic analyses. Preliminary results indicate that OT-101 might prolong progression-free survival in CRC patients, particularly those with low TGFB2 and TGFM6 expression. Further analysis reveals a significant survival benefit in patients with low TGFB2/TGM6 expression. These findings could position OT-101 as a promising treatment for CRC, melanoma, and pancreatic cancer.

Oncotelic Therapeutics (OTCQB: OTLC) announced on May 30, 2024, that its CEO, Dr. Vuong Trieu, will attend the BIO International 2024 meeting in San Diego from June 3-6. The BIO International Convention is the largest biotech industry event, attracting over 18,500 global leaders.

Oncotelic Therapeutics announced that Chief Clinical Officer Dr. Anthony Maida will present at the ASCO 2024 meeting. Key topics include:

1. A meta-analysis (abstract e16318) comparing serious adverse events, overall survival, and progression-free survival in pancreatic adenocarcinoma patients treated with modified FOLFIRINOX versus the standard regimen.

2. A study (abstract e14564) on the prognostic impact of TGFB2 mRNA levels, interferon-gamma receptor activation of IRF5, and CD276/B7-H3 expression in low-grade gliomas.

The presentation aims to provide insights into treatment outcomes and prognostic factors in these cancers.